Ali Moshfegh

Publications
Grants
CV
Public outreach and news

Articles

Article: CANCERS. 2024;16(22):3821
A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Zhong W; Kokhaei P; Mulder TA; Ghaderi A; Moshfegh A; Lundin J; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: IMMUNITY. 2023;56(5):979-997.e11
The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation
Gatsiou A; Tual-Chalot S; Napoli M; Ortega-Gomez A; Regen T; Badolia R; Cesarini V; Garcia-Gonzalez C; Chevre R; Ciliberti G; Silvestre-Roig C; Martini M; Hoffmann J; Hamouche R; Visker JR; Diakos N; Wietelmann A; Silvestris DA; Georgiopoulos G; Moshfegh A; Schneider A; Chan W; Guenther S; Backs J; Kwak S; Selzman CH; Stamatelopoulos K; Rose-John S; Trautwein C; Spyridopoulos I; Braun T; Waisman A; Gallo A; Drakos SG; Dimmeler S; Sperandio M; Soehnlein O; Stellos K
Article: PHARMACEUTICS. 2023;15(4):1148
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99
Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: BIOMEDICINES. 2020;8(6):E170-170
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Journal article: JOURNAL OF IMMUNOLOGY. 2020;204(1_Supplement):59.7
Reduced level of CX3CR1 positive T-cells and monocytes in children with, newly diagnosed, Type 1 diabetes
Dadfar E; Ghaderi A; Moshfegh A; Barcenilla H; Casas R; Samuelsson U
Article: LEUKEMIA. 2018;32(10):2291-2295
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(6):e0198038
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: BMC NEPHROLOGY. 2017;18(1):161
Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial
Mansouri L; Lundwall K; Moshfegh A; Jacobson SH; Lundahl J; Spaak J
Article: PLOS ONE. 2017;12(11):e0187294
Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway
El-Serafi I; Terelius Y; Abedi-Valugerdi M; Naughton S; Saghafian M; Moshfegh A; Mattsson J; Potacova Z; Hassan M
Article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2017;31(1):4-12
Mono-epoxy-tocotrienol-α enhances wound healing in diabetic mice and stimulates in vitro angiogenesis and cell migration
Xu C; Bentinger M; Savu O; Moshfegh A; Sunkari V; Dallner G; Swiezewska E; Catrina S-B; Brismar K; Tekle M
Article: ONCOLOGY LETTERS. 2016;12(4):2782-2788
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions
Hogfeldt T; Jaing C; Mc Loughlin K; Thissen J; Gardner S; Bahnassy AA; Gharizadeh B; Lundahl J; Osterborg A; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: PHARMACOGENOMICS JOURNAL. 2015;15(5):405-413
Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies
El-Serafi I; Fares M; Abedi-Valugerdi M; Afsharian P; Moshfegh A; Terelius Y; Potacova Z; Hassan M
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15_suppl):8556
A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL.
Mellstedt H; Khan S; Hojjat-Farsangi M; Daneshmanesh AH; Vagberg J; Bystrom S; Schultz J; Norin M; Olsson E; Lofberg C; Norstrom C; Olin T; Österborg A; Moshfegh A
Article: PLOS ONE. 2015;10(11):e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: PLOS ONE. 2015;10(11):e0141979
Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation
El-Serafi I; Afsharian P; Moshfegh A; Hassan M; Terelius Y
Article: LEUKEMIA & LYMPHOMA. 2014;55(5):1158-1165
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
Hoegfeldt T; Johnsson P; Grander D; Bahnassy AA; Porwit A; Eid S; Osterborg A; Zekri A-RN; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Article: PLOS ONE. 2014;9(1):e86619
Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation
El-Serafi I; Abedi-Valugerdi M; Potacova Z; Afsharian P; Mattsson J; Moshfegh A; Hassan M
Journal article: BLOOD. 2013;122(21):2619
Gene Expression Analyses At Time Of Diagnosis Indicate Biomarkers Predictive Of Therapeutic Response In Acute Myeloid Leukemia
Lindberg ML; Hååg P; Moshfegh A; Kanter L; Bjorkholm M; Lewensohn R; Kristina V; Stenke L
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(15_suppl):7087
Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.
Daneshmanesh AH; Hojat Farsangi M; Moshfegh A; Khan S; Österborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2013;54(5):996-1003
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures
Hogfeldt T; Bahnassy AA; Kwiecinska A; Osterborg A; Tamm KP; Porwit A; Zekri A-RN; Lundahl J; Khaled HM; Mellstedt H; Moshfegh A
Article: BONE MARROW TRANSPLANTATION. 2013;48(2):284-293
Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?
Sadeghi B; Al-Chaqmaqchi H; Al-Hashmi S; Brodin D; Hassan Z; Abedi-Valugerdi M; Moshfegh A; Hassan M
Article: CELL DEATH & DISEASE. 2013;4(1):e454
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412
Stahl S; Kaminskyy VO; Efazat G; Vaculova AH; Rodriguez-Nieto S; Moshfegh A; Lewensohn R; Viktorsson K; Zhivotovsky B
Article: PLOS ONE. 2013;8(4):e60367
The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease
Al-Chaqmaqchi H; Sadeghi B; Abedi-Valugerdi M; Al-Hashmi S; Fares M; Kuiper R; Lundahl J; Hassan M; Moshfegh A
Article: PLOS ONE. 2013;8(8):e73141
Leukocyte Proliferation and Immune Modulator Production in Patients with Chronic Kidney Disease
Mansouri L; Paulsson JM; Moshfegh A; Jacobson SH; Lundahl J
Article: PLOS ONE. 2013;8(7):e68937
Activation of Wnt/β-Catenin Pathway in Monocytes Derived from Chronic Kidney Disease Patients
Al-Chaqmaqchi HAM; Moshfegh A; Dadfar E; Paulsson J; Hassan M; Jacobson SH; Lundahl J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2013;62(1):51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: PLOS ONE. 2013;8(10):e78339
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Journal article: BLOOD. 2012;120(21):3885
Phosphorylation of Receptor Tyrosine Kinase ROR1 At Tyrosine 641, 646 and Serine 652 residues Might Be of Importance for the Survival of CLL Leukemic Cells
Hojjat-Farsangi M; Daneshmanesh AH; Norin M; Sandin Å; Khan AS; Moshfegh A; Rossmann E; Osterborg A; Mellstedt H
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Lehmann S; Bykov VJN; Ali D; Andren O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: BRITISH JOURNAL OF CANCER. 2012;107(8):1361-1373
miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence
Salim H; Akbar NS; Zong D; Vaculova AH; Lewensohn R; Moshfegh A; Viktorsson K; Zhivotovsky B
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15_suppl):6557
Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.
Mellstedt H; Khan S; Vågberg J; Byström S; Schultz J; Hojat Farsangi M; Mansouri L; Danesh Manesh AH; Österborg A; Moshfegh A
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2012;168(1):105-112
In-vivo extravasation induces the expression of interleukin 1 receptor type 1 in human neutrophils
Paulsson JM; Moshfegh A; Dadfar E; Held C; Jacobson SH; Lundahl J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2011;411(1):156-161
The pattern of gene expression and gene dose profiles of 6-Mercaptopurine- and 6-Thioguanine-resistant human leukemia cells
Karim H; Hashemi J; Larsson C; Moshfegh A; Fotoohi AK; Albertioni F
Article: NEPHROLOGY DIALYSIS TRANSPLANTATION. 2011;26(7):2195-2201
Expression of neutrophil SOD2 is reduced after lipopolysaccharide stimulation: a potential cause of neutrophil dysfunction in chronic kidney disease
Olsson J; Jacobson TAS; Paulsson JM; Dadfar E; Moshfegh A; Jacobson SH; Lundahl J
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2011;38(4):1075-1081
Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer
Jacobson TAS; Lundahl J; Mellstedt H; Moshfegh A
Journal article: BLOOD. 2010;116(21):667
The Proportion of Ph+ CD34+CD38neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study
Mustjoki S; Richter J; Barbany G; Dybedal I; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Jalkanen S; Josefsen D; Koskenvesa P; Lassen C; Latvala K; Majeed W; Malm C; Markevärn B; Moshfegh A; Ohm L; Olofsson T; Olsson-Strömberg U; Rapakko K; Remes K; Stentoft J; Stenke L; Suominen M; Thunberg S; Bjerrum OW; Simonsson B; Porkka K; Hjorth-Hansen H
Article: ONCOGENE. 2010;29(9):1329-1338
Mutant p53 reactivation by PRIMA-1^MET induces multiple signaling pathways converging on apoptosis
Lambert JMR; Moshfegh A; Hainaut P; Wiman KG; Bykov VJN
Journal article: BLOOD. 2009;114(22):3466
Gene Array Biomarkers in Acute Myeloid Leukemia to Predict Remission Duration.
Lindberg ML; Hååg P; Moshfegh A; Kanter L; Lewensohn R; Viktorsson K; Stenke L
Article: BIOCHEMICAL PHARMACOLOGY. 2009;77(8):1410-1417
Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis
Fotoohi AK; Assaraf YG; Moshfegh A; Hashemi J; Jansen G; Peters GJ; Larsson C; Albertioni F
Article: BLOOD PURIFICATION. 2009;28(1):47-52
Monocyte and Neutrophil Chemotactic Activity at the Site of Interstitial Inflammation in Patients on High-Flux Hemodialysis or Hemodiafiltration
Olsson J; Paulsson J; Dadfar E; Lundahl J; Moshfegh A; Jacobson SH
Article: PEDIATRIC ALLERGY AND IMMUNOLOGY. 2007;18(8):643-651
The stress of birth enhances in vitro spontaneous and IL-8-induced neutrophil chemotaxis in the human newborn
Yektaei-Karin E; Moshfegh A; Lundahl J; Berggren V; Hansson L-O; Marchini G
Article: CLINICAL CANCER RESEARCH. 2007;13(5):1503-1510
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Article: KIDNEY INTERNATIONAL. 2007;71(6):582-588
Preserved leukocyte CD11b expression at the site of interstitial inflammation in patients with high-flux hemodiafiltration
Olsson J; Dadfar E; Paulsson J; Lundahl J; Moshfegh A; Jacobson SH
Article: BIOCHEMICAL PHARMACOLOGY. 2006;72(7):816-823
Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside
Fotoohi AK; Wrabel A; Moshfegh A; Peterson C; Albertioni F
Article: PEDIATRIC RESEARCH. 2005;58(1):138-142
Neonatal eosinophils possess efficient eotaxin/IL-5-and N-formyl-methionyl-leucyl-phenylalanine-induced transmigration in vitro
Moshfegh A; Lothian C; Halldén G; Marchini G; Lagercrantz H; Lundahl J
Article: LEUKEMIA. 2004;18(11):1810-1815
Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Österborg A; Mellstedt H
Article: EUROPEAN RESPIRATORY JOURNAL. 2003;21(4):646-651
Lung accumulations of eosinophil granulocytes after exposure to cornstarch glove powder
Grunewald J; Eklund A; Katchar K; Moshfegh A; Lidén C; Lundgren L; Skare L; Tornling G
Article: ALLERGY. 2002;57(12):1200-1204
Increased eosinophil transmigration after nasal allergen challenge in children with allergic asthma and rhinitis
Lönnkvist K; Moshfegh A; Pedroletti C; Hedlin G; Halldén G; Lundahl J
Article: NEPHRON. 2002;91(4):659-665
Impact of hemodialysis membrane and permeability on neutrophil transmigration in vitro
Moshfegh A; Jacobson SH; Halldén G; Thylén P; Lundahl J
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;56(2):161-167
Distinct phenotypic adhesion molecule expression on human cord blood progenitors during early eosinophilic commitment:: Upregulation of β₇ integrins
Lundahl J; Sehmi R; Moshfegh A; Hayes L; Howie K; Upham J; Denburg JA
Article: INFLAMMATION. 2001;25(6):399-404
Increased expression of lymphocytes recruited CD25 and HLA-DR on into the peritoneal cavity in non-infected CAPD patients
Brauner A; Hylander B; Jacobson SH; Moshfegh A; Lundahl J
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1999;50(3):262-269
Methods for simultaneous quantitative analysis of eosinophil and neutrophil adhesion and transmigration
Moshfegh A; Halldén G; Lundahl J
Article: INFLAMMATION. 1998;22(2):123-135
Eotaxin increases the expression of CD11b/CD18 and adhesion properties in IL5, but not fMLP-prestimulated human peripheral blood eosinophils
Lundahl J; Moshfegh A; Grönneberg R; Halldén G
Show more

All other publications

Conference publication: JOURNAL OF IMMUNOLOGY. 2020;204(1)
Reduced level of CX3CR1 positive T-cells and monocytes in children with, newly diagnosed, Type 1 diabetes
Dadfar E; Ghaderi A; Moshfegh A; Barcenilla H; Casas R; Samuelsson U
Meeting abstract: BLOOD. 2019;134:5312
ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Mellstedt H; Ghaderi A; Aschan J; Mozaffari F; Moshfegh A; Sander B; Schultz J; Norin M; Olin T; Drakos E; Rassidakis GZ; Osterborg A; Hojjat-Farsangi M
Meeting abstract: BLOOD. 2019;134:2565
Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells
Hojjat-Farsangi M; Ghaderi A; Daneshmanesh A; Lehto J; Moshfegh A; Kokhaei P; Vagberg J; Olsson E; Lofberg C; Norstrom CC; Schultz J; Norin M; Olin T; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H
Conference publication: PANCREAS. 2017;46(10):1396
ROR1 Targeting Drugs Induced Significant Apoptosis of Pancreatic Cancer Cells
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Schultz J; Vagberg J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Conference publication: KIDNEY INTERNATIONAL REPORTS. 2016;1(4):s14-s15
P30 VITAMIN D RECEPTOR ACTIVATION REDUCES INFLAMMATORY CYTOKINES AND PLASMA MICRORNAS IN MODERATE CHRONIC KIDNEY DISEASE–A RANDOMIZED TRIAL
Mansouri L; Lundwall K; Moshfegh A; Jacobson SH; Lundahl J; Spaak J
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530
First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor
Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Meeting abstract: BLOOD. 2015;126(23):2912
First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Conference publication: JOURNAL OF IMMUNOLOGY. 2015;194:132.6
Down regulation of genes related to selenium signaling pathway in in-vivo transmigrated neutrophils from patients with Chronic Kidney Disease
Mansour L; Moshfegh A; Hylander B; Jacobson S; Lundahi J
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458
The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15)
A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL
Mellstedt H; Khan S; Hojjat-Farsangi M; Daneshmanesh AH; Vagberg J; Bystrom S; Schultz J; Norin M; Olsson E; Lofberg C; Norstrom C; Olin T; Tsterborg A; Moshfegh A
Conference publication: BLOOD. 2014;124(21):1150
Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs
El Serafi I; Abedi-Valugerdi M; Naughton S; Saghafian M; Mattsson J; Moshfegh A; Terelius Y; Potacova Z; Hassan M
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770
Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):3184
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region
Moshfegh A; Hogfeldt T; Jaing C; Lundahl J; Osterborg A; Loughlin KM; Gardner SN; Gharizadeh B; Porwit A; Bahnassy AA; Zekri A-RN; Khaled HM; Mellstedt H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e13561
A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.
Mellstedt H; Daneshmanesh AH; Moshfegh A; Farsangl MH; Khan S; Mlkaelsson E; Vagberg J; Systrom S; Schultz J; Olin T; Ostorborg A
Conference publication: HAEMATOLOGICA. 2014;99:135
TARGETING THE TYROSINE KINASE RECEPTORS ROR1 AND AXL (RTKS) IN BURKITT'S LYMPHOMA
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Moshfegh A; Wagberg J; Bystrom S; Schultz J; Olin T; Osterborg A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2014;99:51-52
ANTI-ROR1 MONOCLONAL ANTIBODIES INDUCED APOPTOSIS OF CLL CELLS AND ALTERED PHOSPHORYLATION OF SRC AND PI3-KINASES
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2013;98:511
GLOBAL GENE ARRAY ANALYSES TO IDENTIFY BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA
Lindberg M; Haag P; Moshfegh A; Kanter L; Lewensohn R; Viktorsson K; Stenke L
Conference publication: HAEMATOLOGICA. 2013;98:404
THE ROLE OF CYP2J2 IN CYCLOPHOSPHAMIDE METABOLISM
El-Serafi I; Afsharian P; Potacova Z; Terelius Y; Moshfegh A; Hassan M
Conference publication: HAEMATOLOGICA. 2013;98:290
ANTI-ROR1 MONOCLONAL ANTIBODY INDUCED APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS THROUGH PI3-KINASE/AKT/MTOR SIGNALING PATHWAY
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2013;98:535
PHOSPHORYLATION OF ROR1 RECEPTOR TYROSINE KINASE AT TYROSINE 641, 646 AND SERINE 652 RESIDUES: THE IMPACT ON THE SURVIVAL OF LEUKEMIC CELLS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Hojjat-Farsangi M; Daneshmanesh A; Norin M; Khan A; Moshfegh A; Osterborg A; Mellstedt H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(15)
Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.
Daneshmanesh AH; Farsangi MH; Moshfegh A; Khan S; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2012;120(21):4583
Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia
Khan AS; Sandin A; Osterborg A; Hojjat-Farsangi M; Mellstedt H; Moshfegh A
Meeting abstract: BLOOD. 2012;120(21):1769
Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway
Daneshmanesh AH; Hojjat-Farsangi M; Sandin A; Khan AS; Moshfegh A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2012;72:3027
Dishevelled proteins are highly upregulated in chronic lymphocytic leukemia
Khan AS; Osterborg A; Moshfegh A; Mellstedt H
Conference publication: MOLECULAR BIOLOGY OF THE CELL. 2012;23
Gene expression profile of monocytes from patients with chronic kidney disease reveals canonical Wnt signaling activation.
Al-Chaqmaqchi H; Moshfegh A; Dadfar E; Paulsson J; Hassan M; Jacobson S; Lundahl J
Conference publication: EXPERIMENTAL HEMATOLOGY. 2012;40(8):S139-S140
DISHEVELLED PROTEINS ARE HIGHLY UPREGULATED IN CHRONIC LYMPHOCYTIC LEUKEMIA
Khan S; Osterborg A; Moshfegh A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2012;97:433
SMALL MOLECULES TARGETING ROR1 INDUCE SPECIFIC KILLING OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
Moshfegh A; Khan S; Vagberg J; Bystrom S; Hojat-Farsangi M; Mansouri L; Sandin A; Manesh AD; Osterborg A; Mellstedt H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15)
Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells
Mellstedt H; Khan S; Vagberg J; Bystrom S; Schultz J; Farsangi MH; Mansouri L; Manesh AHD; Osterborg A; Moshfegh A
Meeting abstract: CANCER RESEARCH. 2011;71:5011
Difference in expression of STAT3 and STAT5b in Swedish and Egyptian patients with activated b-cell subtype of diffuse large b-cell lymphoma
Jacobson T; Bahnassy AA; Lundahl J; Tamm KP; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Conference publication: PROGRESS ON POST-GENOME TECHNOLOGIES AND MODERN NATURAL PRODUCTS, 2011. 2011;:54
GENE EXPRESSION ANALYSIS USING LONG-TERM PRESERVED FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE OF NON-SMALL CELL LUNG CANCER
Moshfegh A
Conference publication: INFLAMMATION RESEARCH. 2011;60:262
GENE EXPRESSION PATTERN IN ACUTE GRAFT VERSUS HOST DISEASE IN TARGET AND NON TARGET ORGANS AFTER CONDITIONING
Al-Chaqmaqchi HAM; Sadeghi B; Al-Hashmi S; Lundahl J; Moshfegh A; Hassan M
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2011;6(6):S745
DOWN REGULATION OF MIR-214 SENSITIZES NSCLC CELLS TO IONIZING RADIATION BY INCREASING THE SENESCENCE SIGNALLING
Salim H; Akbar NS; Zong D; Moshfegh A; Viktorsson K; Lewensohn R; Zhivotovsky B
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2011;6(6):S343-S344
MIR-214 OVEREXPRESSION PROTECTS NSCLC AGAINST RADIOTHERAPY-INDUCED CELL DEATH BY CAUSING IMPAIRED APOPTOTIC SIGNALLING
Akbar NS; Salim H; Zong D; Viktorsson K; Moshfegh A; Lewensohn R; Zhivotovsky B
Conference publication: INFLAMMATION RESEARCH. 2011;60:83
UP-REGULATION OF IL-1R1 AND CHEMOKINE EXPRESSION IN HUMAN NEUTROPHILS FOLLOWING IN VIVO EXTRAVASATION AND IL-1 STIMULATION
Paulsson JM; Moshfegh A; Dadfar E; Held C; Jacobson SH; Lundahl J
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2010;11(2):100-101
NEUTROPHIL IL-1R AND CHEMOKINE EXPRESSION FOLLOWING IN VIVO EXTRAVASATION IN PATIENTS WITH CORONARY ARTERY DISEASE
Paulsson J; Moshfegh A; Dadfar E; Bygden-Nylander A; Held C; Jacobson S; Lundahl J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2010;8(5):134
Global gene analysis reveals ephrin B3 as a potential radio sensitizing target in non small cell lung cancer cells
Stahl S; Vaculova A; Kaminskyy V; Rodriguez-Nieto S; Moshfegh A; Lewensohn R; Viktorsson K; Zhivotovsky B
Conference publication: HELICOBACTER. 2010;15(4):317
Immune response to the gastric pathogen H. pylori: microarray analysis of gastric CD2⁺ cells
Moran AP; O'Donoghue Y; Mashayekhi K; Moshfegh A; Zulquernain SA; O'Keeffe J
Conference publication: BLOOD. 2010;116(21):291-292
The Proportion of Ph+CD34⁺CD38^neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study
Mustjoki S; Richter J; Barbany G; Dybedal I; Fioretos T; Gedde-Dahl T; Gjertsen BT; Hovland R; Jalkanen S; Josefsen D; Koskenvesa P; Lassen C; Latvala K; Majeed W; Malm C; Markevarn B; Moshfegh A; Ohm L; Olofsson T; Olsson-Stromberg U; Rapakko K; Remes K; Stentoft J; Stenke L; Suominen M; Thunberg S; Bjerrum OW; Simonsson B; Porkka K; Hjorth-Hansen H
Conference publication: BLOOD. 2009;114(22):1346
Gene Array Biomarkers in Acute Myeloid Leukemia to Predict Remission Duration.
Lindberg ML; Haag P; Moshfegh A; Kanter L; Lewensohn R; Viktorsson K; Stenke L
Conference publication: HAEMATOLOGICA. 2007;92:33
Gene expression profiling of peripheral blood T cells in patients with indolent B-cell chronic lymphocytic leukemia (B-CLL)
Kiaii K; Osterborg A; Mashayekhi K; Moshfegh A; Choudhury A; Mellstedt H
Doctoral thesis: 2001
The biological mechanisms in neutrophil and eosinophil adhesion and transmigration in vitro and theur relation to the inflammatory process in vivo
Moshfegh A
Show more

Grants

ROR1 - a tyrosine kinase receptor for targeted therapy
Swedish Research Council
1 January 2013 - 31 December 2015

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2024-2027

Degrees and Education

Doctor Of Philosophy, Degree of Doctor, The biological mechanisms in neutrophil and eosinophil adhesion and transmigration in vitro and theur relation to the inflammatory process in vivo, Department of Medicine, Solna, Karolinska Institutet, 2002
Licentiate Degree, DEPT OF LABORATORY MEDICINE, Karolinska Institutet, 1999

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI